Abstract
Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have